Entrada Therapeutics (TRDA) Cash & Equivalents (2020 - 2026)

Entrada Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $76.4 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 12.69% year-over-year to $76.4 million in Q1 2026; TTM through Mar 2026 was $76.4 million, a 12.69% increase from a year earlier, with the FY2025 full-year figure at $90.4 million, down 10.69% from the prior year.
• Cash & Equivalents declined to $76.4 million in Q1 2026 per TRDA's latest filing, from $90.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $227.6 million in Q1 2023 and bottomed at $45.2 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $78.0 million (2024), against an average of $90.2 million.
• Across the five-year window, Cash & Equivalents sank 84.49% in 2022 and surged 168.96% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $45.2 million in 2022, then surged by 49.7% to $67.6 million in 2023, then surged by 49.72% to $101.2 million in 2024, then retreated by 10.69% to $90.4 million in 2025, then fell by 15.43% to $76.4 million in 2026.
• Per Business Quant, the three latest TRDA Cash & Equivalents figures stand at $76.4 million (Q1 2026), $90.4 million (Q4 2025), and $93.3 million (Q3 2025).